Prospective-randomized Adaptive Study, With Active Control to Evaluate the Efficacy and Safety of Interleukin (IL)-17 Inhibitor Treatment Versus Low Doses of IL-2 Versus Indirect IL-6 Inhibitor in Hospitalized Patients With Severe Forms of COVID-19
Latest Information Update: 05 May 2023
At a glance
- Drugs Aldesleukin (Primary) ; Colchicine (Primary) ; Ixekizumab (Primary)
- Indications COVID-19 pneumonia
- Focus Therapeutic Use
- Acronyms STRUCK
Most Recent Events
- 26 Jul 2022 Status changed from recruiting to completed.
- 01 Feb 2021 New trial record